STOCK TITAN

Solventum Corporation (SOLV) Stock News

SOLV NYSE

Solventum Corporation (NYSE: SOLV) generates a steady flow of news that reflects its role in the medical instruments and supplies sector and its focus on MedSurg, Dental Solutions and Health Information Systems. News about Solventum often highlights developments in advanced wound care, portfolio changes, capital allocation decisions and strategic initiatives intended to support long-term growth.

Recent announcements include agreements and completion of the acquisition of Acera Surgical, a bioscience company focused on fully engineered materials for regenerative wound care. These updates describe how Solventum is expanding its MedSurg portfolio into the synthetic tissue matrices technology space within acute care settings. Other news covers clinical and scientific developments, such as international consensus recommendations on the use of closed incision negative pressure therapy with reticulated open cell foam dressings, which relate directly to Solventum Prevena Therapy and its application across surgical specialties.

Investors and healthcare professionals following SOLV news will also see coverage of financial results, including quarterly earnings releases and guidance updates, as well as information about Solventum’s “Transform for the Future” initiative to reshape its cost structure and support innovation. Capital markets and balance sheet actions, such as cash tender offers for outstanding notes, the sale of the purification and filtration business to Thermo Fisher Scientific Inc., and the authorization of a share repurchase program, are reported through both press releases and SEC filings.

Additional news items may feature recognition of operational capabilities, such as the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for supply chain strength in the MedSurg segment, and participation in healthcare investor conferences. By reviewing the SOLV news feed on a regular basis, readers can track how Solventum’s strategic decisions, clinical evidence, portfolio moves and financial performance are communicated to the market over time.

Rhea-AI Summary

Solventum (NYSE: SOLV) reported third-quarter 2026 sales of $1.9 billion, down year over year, while raising its full-year adjusted earnings outlook.

Reported sales fell 7.0%; organic sales fell 2.8%, reflecting a 630-basis-point reversal of second-quarter advance orders ahead of the enterprise resource planning system cutover. The net loss was $12 million, or $0.07 per diluted share, versus earnings of $1,266 million a year earlier, when a business-sale gain boosted results. Adjusted diluted earnings fell 3.6% to $1.45. Operating cash flow rose to $177 million.

Solventum expects organic growth toward the high end of 2.5%–3.0% and raised adjusted EPS guidance to $7.20–$7.30, while affirming $200 million–$300 million in free cash flow. System cutovers are complete, and approximately 90% of 3M transition service agreements have been exited.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
-
Rhea-AI Summary

Solventum (SOLV) received FDA 510(k) clearance for the combined use of Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy.

The clearance follows Solventum's acquisition of Acera Surgical in December 2025. Restrata is a fully resorbable synthetic matrix that provides structural support for soft tissue repair. V.A.C. Therapy applies negative pressure to create an environment that supports wound healing and helps maintain contact between the matrix and wound bed.

Restrata's resistance to enzymatic degradation aligns with the V.A.C. Peel and Place Dressing's wear time of up to seven days. Solventum said the combination may allow fewer dressing changes, less disruption to the healing environment and a more predictable workflow for care teams.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
-
Rhea-AI Summary

Solventum (SOLV) will release its third quarter fiscal 2026 financial results on November 5, 2026, after U.S. financial markets close. Management will then host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss the results. A replay, earnings release, presentation slides and supplemental financial disclosures will be available on the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
earnings date
Rhea-AI Summary

Solventum (SOLV) will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 9, 2026, starting around 10:15 a.m. EDT in Boston, Massachusetts.

A live webcast and an archived replay of the session will be available on the company’s investor website at investors.solventum.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary

Solventum (NYSE: SOLV) reported second quarter 2026 net sales of $2.2 billion, up 2.2% reported and 9.5% organically. GAAP diluted EPS was $0.53, while adjusted diluted EPS was $2.55, up 50.9% year over year. Operating cash flow was $227 million and free cash flow $144 million, both above company expectations.

Organic growth was broad-based across segments, and adjusted operating margin rose to 28.4%, up 650 bps, helped by an IEEPA tariff refund and ERP-related timing benefits. Solventum announced its intent to separate the Health Information Systems segment to sharpen its focus as a MedTech company.

For full-year 2026, the company raised guidance: organic sales growth to 2.5%–3.0% (3.5%–4.0% excluding ~100 bps SKU exits), adjusted EPS to $7.10–$7.20, and free cash flow to $200–$300 million, all based on non-GAAP measures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
-
Rhea-AI Summary

Solventum (NYSE: SOLV) announced its intention to separate its Health Information Systems (HIS) business as part of an ongoing portfolio optimization and three-phase transformation strategy. Solventum is evaluating multiple separation structures, including creating an independent company, combining HIS with a scaled player, or pursuing another transaction type, with the goal of maximizing shareholder value.

HIS is a healthcare software business generating $1.4 billion in annual sales, serving more than 75% of U.S. hospitals, processing about 660 million clinical documents monthly, and operating in an estimated $10 billion addressable market growing 5–6% annually. According to Solventum, a separation would allow Solventum to focus on its MedSurg and Dental Solutions businesses, while giving HIS dedicated management, strategic focus, and capital allocation flexibility. The company is targeting transaction completion within 12–18 months, but no final decision on structure or timing has been made and there is no assurance a separation will occur.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
none
Rhea-AI Summary

Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after U.S. markets close. Management will then host an earnings webcast to review the quarter and may discuss other forward-looking and material information.

The webcast is scheduled for 3:30 p.m. CDT / 4:30 p.m. EDT and can be accessed via https://investors.solventum.com. According to Solventum, investors can join by phone using U.S. dial-in +1 (800) 715-9871, international dial-in +1 (646) 307-1963, and conference ID 6342275. A replay, the earnings release, slides, and supplemental financial disclosures will be available afterward on the Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
earnings date
-
Rhea-AI Summary

Solventum (NYSE: SOLV) announced that its management will participate in a fireside chat at the Jefferies Healthcare Conference in New York on Wednesday, June 3, 2026, at approximately 9:55 a.m. EDT. A live and archived webcast will be available at investors.solventum.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

Solventum (NYSE: SOLV) will participate in the BofA Securities Health Care Conference on Wednesday, May 13, 2026, with a management fireside chat beginning at approximately 10:00 a.m. PDT in Las Vegas. A live and archived replay will be available on the company's investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
Rhea-AI Summary

Solventum (NYSE: SOLV) reported Q1 2026 results for the quarter ended March 31, 2026. Net sales $2.007B (reported -3.0%; organic +2.1%). GAAP diluted EPS $0.07; adjusted diluted EPS $1.48 (up 10.6%). Operating cash flow was $(189)M; free cash flow $(273)M.

Company affirmed full-year 2026 guidance: organic sales +2.0%–+3.0%, adjusted EPS toward high end of $6.40–$6.60, and free cash flow ~ $200M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags

FAQ

What is the current stock price of Solventum (SOLV)?

Solventum (SOLV) last closed at $84.50.

What is the market cap of Solventum (SOLV)?

The market cap of Solventum (SOLV) is approximately $14.3B.